Document is current

Article History

Received: 25 August 2022

Revised: 19 January 2023

Accepted: 26 January 2023

First Online: 3 February 2023

Declarations

:

: This funding organization had no role in the design or conduct of this research.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the ethics committee of Kyoto University Graduate School of Medicine (Kyoto, Japan) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.

: Manabu Miyata has received research grants from Alcon Japan, Novartis Pharma, and Santen Pharmaceuticaland a speaker honorarium from HOYA, Santen Pharmaceutical, Bayer Yakuhin, Senju Pharmaceutical, and Kowa Pharmaceutical. Sotaro Ooto has received a speaker honorarium from Bayer Yakuhin, Kowa Pharmaceutical, Janssen Pharmaceutical, Novartis Pharma, AMO Japan, Santen Pharmaceutical, Alcon Japan, and Senju Pharmaceutical. Hiroshi Tamura has received a grant from Findex and a speaker honorarium from Bayer Yakuhin, Novartis Pharma, Santen Pharmaceutical, SUNTORY, and Otsuka Pharmaceutical. Naoko Ueda-Arakawa has received a speaker honorarium from Santen Pharmaceutical, Novartis Pharma, and Chugai Pharmaceutical. Yuki Muraoka has received grants from Bayer Yakuhin, Novartis Pharma, and Alcon Japan and a speaker honorarium from Canon, Santen Pharmaceutical, Senju Pharmaceutical, Bayer Yakuhin, Novartis Pharma, AMO Japan, HOYA, and Johnson & Johnson. Masahiro Miyake has received a grant from Novartis Pharma and a speaker honorarium from Bayer Yakuhin, Kowa Pharmaceutical, Alcon Japan, HOYA, Novartis Pharma, AMO Japan, Santen Pharmaceutical, Senju Pharmaceutical, Johnson & Johnson, and Chugai Pharmaceutical. Ayako Takahashi has a speaker honorarium from Bayer Yakuhin, Novartis Pharma, Santen Pharmaceutical, and MSD. Akihito Uji has received a speaker honorarium from Canon, Bayer Yakuhin, Novartis Pharma, Santen Pharmaceutical, Senju Pharmaceutical, and HOYA. Kenji Yamashiro has received a speaker honorarium from Novartis Pharma, Bayer Yakuhin, Santen Pharmaceutical, Alcon Pharma, Senju Pharmaceutical, Kowa Pharmaceutical, and Chugai Pharmaceutical. Akitaka Tsujikawa has received grants from Canon, Findex, Santen Pharmaceutical, Kowa Pharmaceutical, Pfizer, AMO Japan, Senju Pharmaceutical, Wakamoto Pharmaceutical, Alcon Japan, Novartis Pharma, Otsuka Pharmaceutical, Bayer Yakuhin, and Nitten Pharmaceutical; a speaker honorarium from Bayer Yakuhin, Senju Pharmaceutical, Novartis Pharma, Santen Pharmaceutical, Alcon Pharma, Alcon Japan, AbbVie GK, AMO Japan, Kowa Pharmaceutical, Canon Otsuka Pharmaceutical, and Wakamoto Pharmaceutical; and consultant fee from Senju Pharmaceutical, Bayer Yakuhin, Novartis Pharma, HOYA, Ellex, Allegan Japan, Eisai, Daiichi-Sanyo, Chugai Pharmaceutical, and MSD. The other authors had no conflict of interest.